Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | KRAS | P01116 | 1/20 | 0.40 |
| ▸ | IL2 | P60568 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10441887 | 0.89 | CES2 (0.64) | CES2CES1POLBRAB9AKMT2A | |
| SCHEMBL7598628 | 0.87 | CA12 (0.43) | RAB9ANPC1GAA | |
| SCHEMBL8056782 | 0.81 | CA12 (0.53) | CES2CES1POLBRAB9AKRAS | |
| SCHEMBL30632216 | 0.81 | CA12 (0.53) | CES2CES1POLBRAB9AKRAS | |
| SCHEMBL6359374 | 0.79 | CES2 (0.56) | CES2CES1ACHEKMT2AHDAC4 | |
| SCHEMBL6355686 | 0.79 | POLB (0.46) | CES2CES1POLBRAB9AKRAS | |
| SCHEMBL15445363 | 0.79 | ALDH1A1 (0.39) | RAB9ANPC1 | |
| SCHEMBL9700205 | 0.76 | CES2 (0.50) | CES2CES1RAB9AKRASIL2 | |
| SCHEMBL12160758 | 0.75 | CES2 (0.54) | CES2CES1POLBACHEKMT2A | |
| SCHEMBL544028 | 0.75 | CES2 (0.54) | CES2CES1ACHEKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050124498-A1 | Halobenzyl substituted phenylaceto esters and amides and use thereof for prevention of harmful organisms | BAYER CROPSCIENCE AG (DE) | 2005-06-09 | — | — | US | disclosed |
| EP-1483248-A1 | HALOBENZYL SUBSTITUTED PHENYLACETO ESTERS AND AMIDES AND USE THEREOF FOR PREVENTION OF HARMFUL ORGANISMS | Bayer CropScience Aktiengesellschaft (DE) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003074496-A1 | HALOBENZYL SUBSTITUTED PHENYLACETO ESTERS AND AMIDES AND USE THEREOF FOR PREVENTION OF HARMFUL ORGANISMS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124498-A1 | Halobenzyl substituted phenylaceto esters and amides and use thereof for prevention of harmful organisms | HDHD5, GNPAT, PGLS | CES2 62/4885CES1 155/4885POLB 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.